REVENIR Trademark

Trademark Overview

On Wednesday, March 15, 2023, a trademark application was filed for REVENIR with the United States Patent and Trademark Office. The USPTO has given the REVENIR trademark a serial number of 79370662. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, November 5, 2024. This trademark is owned by Congruence Therapeutics Inc.. The REVENIR trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Platform as a service (PaaS) featuring computer software platforms for computational drug discovery
revenir

General Information

Serial Number79370662
Word MarkREVENIR
Filing DateWednesday, March 15, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 5, 2024

Trademark Statements

Translation of Words in MarkThe English translation of "REVENIR" in the mark is "to revert".
Goods and ServicesPlatform as a service (PaaS) featuring computer software platforms for computational drug discovery

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, May 26, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCongruence Therapeutics Inc.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCA
Party NameCongruence Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCA

Trademark Events

Event DateEvent Description
Thursday, May 25, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, May 26, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 30, 2023APPLICATION FILING RECEIPT MAILED
Tuesday, December 12, 2023ASSIGNED TO EXAMINER
Friday, December 22, 2023NON-FINAL ACTION WRITTEN
Saturday, December 23, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, January 8, 2024REFUSAL PROCESSED BY MPU
Monday, January 8, 2024NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, January 31, 2024REFUSAL PROCESSED BY IB
Monday, July 8, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 8, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 8, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 30, 2024NON-FINAL ACTION E-MAILED
Tuesday, July 30, 2024NON-FINAL ACTION WRITTEN
Tuesday, July 30, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, September 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 24, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 25, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 16, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, October 18, 2024NEW REPRESENTATIVE AT IB RECEIVED
Wednesday, October 23, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, October 23, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, November 5, 2024PUBLISHED FOR OPPOSITION
Tuesday, November 5, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Saturday, November 9, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

Related Keywords

revenir platforms computational drug discovery software computer service paas featuring platform